Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roche Holding AG (RHHBY) Analyst/Investor Day Transcript
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
| Pharmaceuticals Industry | Healthcare Sector | Thomas Schinecker CEO | LSE Exchange | US7711951043 ISIN |
| CH Country | 103,249 Employees | 13 Mar 2026 Last Dividend | 27 Feb 2014 Last Split | - IPO Date |
Roche Holding AG is a globally recognized healthcare company that combines its strengths in both pharmaceuticals and diagnostics. With a rich heritage dating back to 1896, the company has established a significant presence across various continents including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. Roche is committed to improving health and well-being by providing innovative solutions and cutting-edge products in multiple therapeutic areas and diagnostics. The company's headquarters are strategically located in Basel, Switzerland, ensuring a pivotal role in the global healthcare sector.
Roche Holding AG offers a diverse portfolio of products and services across a broad spectrum of medical needs and diagnostic requirements. The company’s offerings can be categorized into pharmaceutical products and diagnostic solutions.
Through its relentless pursuit of innovation and its expansive portfolio, Roche Holding AG is at the forefront of shaping the future of healthcare by addressing some of the most challenging medical needs and advancing global health.